APOE ɛ4 carriership determines a faster plasma p-tau217 progression in Aβ-positive individuals.

ABSTRACT:

Introduction

It is unclear whether the different Alzheimer's disease (AD) progression trajectories of apolipoprotein E (APOE) ɛ4 carriers is reflected by blood phosphorylated tau (p-tau) analytes.

Methods

We assessed longitudinal trajectories in plasma p-tau181, 217, and 231, in amyloid beta-positive (A+) and negative (A-) APOE ɛ4 carriers (E+) or non-carriers (E-). We included 2039 participants from the observational Translational Biomarkers in Aging and Dementia (TRIAD) and Alzheimer's Disease Neuroimaging Initiative cohorts, categorized into 840 A-E-, 251 A-E+, 386 A+E4-, and 616 A+E4+. Longitudinal data were available for 1045 participants.

Results

In TRIAD, ALZpath p-tau217 (β = 0.45, p = 0.02) and p-tau217+^Janssen (β = 0.67, p = 0.002), and in ADNI p-

SUBMITTER: Woo MS 

PROVIDER: S-EPMC12741900 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature